DPC TO DEBUT IMMULITE 1000 AUTOMATED IMMUNOASSAY SYSTEM.Diagnostic Products Corporation (NYSE NYSE See: New York Stock Exchange :DP), Los Angeles, will release an addition to the IMMULITE family of systems, the IMMULITE(R) 1000 later this year. "This is an exciting time for DPC DPC Department of Premier and Cabinet (Victoria, Australia) DPC Dutch Power Cows DPC Deferred Procedure Calls (Microsoft Windows NT 4. and the further development of the IMMULITE range of products," said Michael Ziering, president and chief executive officer of DPC. "The IMMULITE 1000 has been developed based on the successful IMMULITE platform. The new IMMULITE 1000 provides enhanced ease of use and more productivity. Features like Windows(R) 2000 software, a touch screen user interface, consolidated instrument footprint, Remote Diagnostics, on-board dilutions for selected assays and positive secondary sample identification will provide the user with a new system technology and instrumentation built upon the history and reputation of the highly successful IMMULITE." DPC has successfully combined innovative instrumentation design with advanced immunoassay Immunoassay An assay that quantifies antigen or antibody by immunochemical means. The antigen can be a relatively simple substance such as a drug, or a complex one such as a protein or a virus. tests to build company growth. This year, shipments of IMMULITE products, including the company's most advanced instruments, grew 16% over the first quarter of 2001, and product line sales reached $62.4 million, 83% of the total sales of the company. With growth of 14% in a market that grew in the mid-single digits, DPC increased its worldwide market share significantly. The IMMULITE 1000 will launch with the same menu and reagents as those available on the IMMULITE platform, for an unrivalled breadth of menu of almost 100 assays. The menu includes routine tests such as those for thyroid function, reproductive endocrinology, cardiac status and tumor markers Tumor Markers Definition Tumor markers are measurable biochemicals that are associated with a malignancy. They are either produced by tumor cells (tumor-derived) or by the body in response to tumor cells (tumor-associated). ; as well as esoteric tests such as those for infectious disease, diabetes and bone metabolism. The IMMULITE 1000 is scheduled for availability throughout the world in the second half of 2002 (pending regulatory approvals). The system will be previewed at the American Association for Clinical Chemistry (AACC AACC American Association of Community Colleges (formerly American Association of Junior Colleges) AACC American Association for Clinical Chemistry AACC American Association of Cereal Chemists AACC Anne Arundel Community College ) and the Clinical Laboratory Management Association (CLMA CLMA Clinical Laboratory Management Association CLMA Contact Lens Manufacturers Association CLMA Cariboo Lumber Manufacturers' Association (Canada) CLMA Canadian Lumber Manufacturers Association CLMA Collegiate Middle Level Association ) meetings this summer. About Diagnostic Products Corporation Founded in 1971, Diagnostic Products Corporation (DPC) is the global leader dedicated exclusively to immunodiagnostic immunodiagnostic pertaining to diagnosis by immune reactions. testing. The company's product menu includes over 400 tests to measure microorganisms, hormones, drugs and other medically important substances present at infinitesimal in·fin·i·tes·i·mal adj. 1. Immeasurably or incalculably minute. 2. Mathematics Capable of having values approaching zero as a limit. n. 1. concentrations in body fluids and tissues. DPC also designs and manufactures automated laboratory instrumentation which provides fast, accurate results while reducing labor and reagent costs. DPC sells its products to hospitals, clinics and laboratories domestically and in over 100 international countries. For more information, visit http://www.dpcweb.com or call 310/645-8200. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion